Date of Publication: May 27, 2025 - The newly released report titled ‘Cancer Biomarkers Market’ offers a structured analysis of the current state and future outlook of the global market. Covering historical trends and future projections from 2025 to 2035, the study evaluates how the market size has shifted over time and what lies ahead in terms of growth and development. The report focuses on evidence-based trends, providing insights into demand shifts, market structure, and broader industry patterns.
The cancer biomarker market size is projected to grow from $ 28.6 billion in 2024 to $ 46.7 billion by 2035, representing a CAGR of 5% during the forecast period from 2024 to 2035. The report assesses this growth by examining real-world data, strategic decisions made by key companies, and movement across regional markets. Rather than making speculative forecasts, it presents information in a way that supports grounded business decision-making and planning. [Source of Information - https://www.rootsanalysis.com/reports/cancer-biomarkers-market/253.html ]
The research investigates key elements influencing the market and offers a detailed breakdown of major operational categories. It explores business expansion efforts, investment themes, and product distribution strategies used across the industry. Readers are provided with a neutral overview of the ‘Cancer Biomarkers Market forecast, grounded in verified insights rather than promotional narratives.
Growth rate
Type of Biomarker
HER2
MET
EGFR
PD-L1
NTRK
ALK
Novel Biomarkers
Other Biomarkers
Type of Cancer
Breast Cancer
Prostate Cancer
Colorectum Cancer
Lung Cancer
Thyroid Cancer
Bladder Cancer
Melanoma
Non-Hodgkins Lymphoma
Endometrial Cancer
Kidney Cancer
Leukemia
Key Geographical Regions
North America
Europe
Asia-Pacific
Rest of the World
Leading Market Players
Agilent
ARUP Laboratories
BioReference
Foundation Medicine
OncoDNA
Q² Solutions
Thermo Fisher Scientific
YuceBio
Asper Biogene
Caris Life Sciences
CeGaT
Genekor Medical
Guardant Health
Labcorp
MedGenome
NeoGenomics Laboratories
Nonacus
Oxford Gene Technology
Personal Genome Diagnostics
PhenoPath
Positive Biosciences
Quest Diagnostics
Tempus
The report includes a dedicated analysis of major players contributing to the ‘Cancer Biomarkers Market growth. Some of the top companies in ‘Cancer Biomarkers include Agilent, ARUP Laboratories, BioReference, Foundation Medicine, OncoDNA, Q² Solutions, Thermo Fisher Scientific, YuceBio, Asper Biogene, Caris Life Sciences, CeGaT, Genekor Medical, Guardant Health, Labcorp, MedGenome, NeoGenomics Laboratories, Nonacus, Oxford Gene Technology, Personal Genome Diagnostics, PhenoPath, Positive Biosciences, Quest Diagnostics, Tempus.
These organizations have been profiled in terms of their operational scale, product offerings, and strategic initiatives. Their positions in regional and global markets are discussed with reference to product performance, market engagement, and business continuity strategies. The report highlights how these players have shaped the market over time, offering insight into their long-term direction and business focus.
The study also touches on a range of external factors such as policy changes, access to distribution networks, and market regulations. These elements play a role in shaping the trajectory of the market for ‘Cancer Biomarkers and influence how companies develop and implement their strategic approaches. Regional patterns, investment outlooks, and evolving pricing structures are also evaluated to provide a well-rounded view of the ‘Cancer Biomarkers industry share.
Strategic movements such as partnerships, acquisitions, and new market entries are assessed as part of the broader market landscape. The report draws attention to how businesses are responding to demand patterns, operating in changing environments, and aligning with regional policies.
Research Methodology
The report has been developed using a combination of primary and secondary research techniques. Company websites, SEC filings, investor presentations, public records, and interviews with industry participants have been utilized to build a credible and balanced dataset. These methods have ensured accurate findings and insights, enabling stakeholders to better navigate the ‘Cancer Biomarkers Market and make informed decisions.
To learn more about the report or to request a customized version tailored to your business requirements, feel free to get in touch with our team. We’re here to assist with further details and support your strategic planning initiatives.